Lindner W, Vossbeck S, Hummler H, Pohlandt F Delivery room management of extremely low birth weight infants: spontaneous breathing or intubation? Pediatrics. 1999 May;103(5 Pt 1):961-7.
Lista G, Fontana P, Castoldi F, Cavigioli F, Dani C Does sustained lung inflation at birth improve outcome of preterm infants at risk for respiratory distress syndrome? Neonatology. 2011;99(1):45-50. doi: 10.1159/000298312.
Rabi Y, Singhal N, Nettel-Aguirre A Room-air versus oxygen administration for resuscitation of preterm infants: the ROAR study. Pediatrics. 2011 Aug;128(2):e374-81. doi: 10.1542/peds.2010-3130. Erratum in: Pediatrics. 2011 Dec;128(6):1212.
Schmölzer GM, Te Pas AB, Davis PG, Morley CJ Reducing lung injury during neonatal resuscitation of preterm infants. J Pediatr. 2008 Dec;153(6):741-5. doi: 10.1016/j.jpeds.2008.08.016. Review.
SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network , Finer NN, Carlo WA, Walsh MC, Rich W, Gantz MG, Laptook AR, Yoder BA, Faix RG, Das A, Poole WK, Donovan EF, Newman NS, Ambalavanan N, Frantz ID 3rd, Buchter S, Sánchez PJ, Kennedy KA, Laroia N, Poindexter BB, Cotten CM, Van Meurs KP, Duara S, Narendran V, Sood BG, O'Shea TM, Bell EF, Bhandari V, Watterberg KL, Higgins RD. Early CPAP versus surfactant in extremely preterm infants. N Engl J Med. 2010 May 27;362(21):1970-9. doi: 10.1056/NEJMoa0911783. Erratum in: N Engl J Med. 2010 Jun 10;362(23):2235.
te Pas AB, Walther FJ A randomized, controlled trial of delivery-room respiratory management in very preterm infants. Pediatrics. 2007 Aug;120(2):322-9. Erratum in: Pediatrics. 2007 Oct;120(4):936.
Vyas H, Milner AD, Hopkin IE, Boon AW Physiologic responses to prolonged and slow-rise inflation in the resuscitation of the asphyxiated newborn infant. J Pediatr. 1981 Oct;99(4):635-9.
Sustained Inflations to Achieve Lung Aeration at Birth - a Randomized Control Trial
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
